An optimal "Click" formulation strategy for antibody-drug conjugate synthesis

Area of Science:

• Chemical Biology
• Medicinal Chemistry
• Bioconjugation Chemistry

Background:

• Copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC) is a versatile bioconjugation method.
• Antibody-drug conjugates (ADCs) are crucial therapeutics with significant synthesis challenges.

Purpose of the Study:

• To kinetically characterize CuAAC formulation processes for optimizing ADC synthesis.
• To elucidate the impact of alkyne and azide positioning on reaction kinetics in ADC development.

Main Methods:

• Mimicking ADC synthesis using small molecules to study reaction kinetics.
• Investigating the influence of drug and antibody functionalization (alkyne/azide) on CuAAC rates.
• Evaluating the effect of metal-chelating properties of antibodies on reaction kinetics.

Main Results:

• Reaction rates for alkyne-containing drugs varied based on antibody azide type (metal-chelating vs. non-metal-chelating).
• For alkyne-containing antibodies, reaction rates showed dependence on drug azide type and concentration.
• Identified unique kinetic behaviors influenced by the location of alkyne and azide functionalities.

Conclusions:

• Developed an optimized "click" formulation strategy for rapid and cost-effective ADC synthesis.
• Demonstrated the importance of kinetic characterization for designing efficient CuAAC-based ADC manufacturing processes.
• Provided insights into controlling reaction rates by strategic placement of alkyne and azide groups in ADC synthesis.